PHRM Stock Overview
A specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
PharmaTher Holdings Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.22 |
| 52 Week High | CA$0.43 |
| 52 Week Low | CA$0.08 |
| Beta | 3.42 |
| 1 Month Change | -10.20% |
| 3 Month Change | 2.33% |
| 1 Year Change | 100.00% |
| 3 Year Change | -56.00% |
| 5 Year Change | n/a |
| Change since IPO | 12.82% |
Recent News & Updates
Shareholder Returns
| PHRM | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 12.8% | -3.1% | -1.4% |
| 1Y | 100.0% | 44.2% | 11.2% |
Return vs Industry: PHRM exceeded the Canadian Pharmaceuticals industry which returned 44.2% over the past year.
Return vs Market: PHRM exceeded the Canadian Market which returned 11.2% over the past year.
Price Volatility
| PHRM volatility | |
|---|---|
| PHRM Average Weekly Movement | 19.0% |
| Pharmaceuticals Industry Average Movement | 14.2% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in CA Market | 17.4% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: PHRM's share price has been volatile over the past 3 months.
Volatility Over Time: PHRM's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | Fabio Chianelli | www.pharmather.com |
PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company’s product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson’s disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures.
PharmaTher Holdings Ltd. Fundamentals Summary
| PHRM fundamental statistics | |
|---|---|
| Market cap | CA$19.47m |
| Earnings (TTM) | -CA$4.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs PHRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHRM income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$4.35m |
| Earnings | -CA$4.35m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PHRM perform over the long term?
See historical performance and comparison